@article{ATM21777,
author = {Viola W. Zhu and Sai-Hong Ignatius Ou},
title = {Pacific Rim redux: lorlatinib, the ultimate Jaeger?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Lorlatinib is the most potent anaplastic lymphoma kinase (ALK) inhibitor to date based on pre-clinical models and also has excellent central nervous system penetration with an efflux/influx ratio of 1.5 (1). Emerging phase 1/2 data have demonstrated its efficacy in patients after disease progression on first- and second-generation ALK inhibitors (2).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21777}
}